GABRR3

Gamma-aminobutyric acid receptor subunit rho- · A8MPY1 · GABRR3 on Sugi Atlas →

4,761 patent compounds predicted against GABRR3, 3,827 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Fumaric Acid (SCHEMBL786567)	0.58	2/20
Maleic Acid (SCHEMBL786851)	0.58	2/20
Maleic Acid (SCHEMBL558296)	0.55	2/20
Fumaric Acid (SCHEMBL558298)	0.55	2/20
Fumaric Acid (SCHEMBL1835362)	0.52	2/20
Fumaric Acid (SCHEMBL1926550)	0.50	2/20
Ethylenediamine (SCHEMBL909940)	0.47	2/20
Acrylic Acid (SCHEMBL1399480)	0.46	2/20
Monoethanolamine (SCHEMBL1834156)	0.42	2/20
Acrylic Acid (SCHEMBL1085535)	0.39	2/20
Acrylic Acid (SCHEMBL1399478)	0.39	2/20
SCHEMBL1694419	0.39	2/20
SCHEMBL1694421	0.39	2/20
Propionic Acid (SCHEMBL45569)	0.36	2/20
Acrylamide (SCHEMBL1417837)	0.33	2/20
Acrylamide (SCHEMBL1908217)	0.33	2/20
Gamma-Aminobutyric Acid (SCHEMBL190459)	1.00	1/20
Gamma-Aminobutyric Acid (SCHEMBL297249)	0.88	1/20
5-Aminovaleric Acid (SCHEMBL887118)	0.82	1/20
SCHEMBL35564	0.78	1/20

Clinical trials — most relevant to GABRR3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Computational Assessment of GABA Receptor Modulation in PTSD	PHASE4	RECRUITING
Safety of Ramelteon in Elderly Subjects	PHASE4	COMPLETED
Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia	PHASE3	COMPLETED
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia	PHASE2	COMPLETED
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia	PHASE2	COMPLETED
Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome	PHASE2	RECRUITING
A Multicenter Study of NAP (AL-108) in Schizophrenia	PHASE2	COMPLETED
Neurosteroids and Acute Alcohol Intoxication in Humans	PHASE1	UNKNOWN
MEG Study of Acute STX209 Effects in ASD	EARLY_PHASE1	COMPLETED
Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression	EARLY_PHASE1	RECRUITING
Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T	EARLY_PHASE1	UNKNOWN
Pilot Study Evaluating Neuro-Imaging Correlates of Epigenetic Finding in Prediction of Chronic Postsurgical Pain	nan	UNKNOWN
GABA Biomarkers in Dravet Syndrome	nan	RECRUITING
The Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Working Memory	nan	COMPLETED
Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy	nan	UNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
A Positional Cloning Study on Schizophrenia	nan	COMPLETED
Functional Study of Inhibitory Neurotransmission in the Human Epileptic Brain.	nan	RECRUITING
Potential Synergistic Effect of Combined Blood Flow Restriction Training and Betaine Supplementation on Skeletal Muscle	nan	COMPLETED
Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder	nan	UNKNOWN
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction	nan	RECRUITING
Acute Intermittent Hypoxia in Traumatic Brain Injury	nan	COMPLETED
Pharmacogenetics of Alcohol: Treatment Implications	nan	COMPLETED
Y-3 Injection Through Skull Bone Marrow in the Treatment of Acute Malignant Middle Cerebral Artery Infarction (SOLUTION)	nan	COMPLETED
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms	nan	COMPLETED
Clinical-Genetic Variation in GABA/Alcohol Sensitivity	nan	COMPLETED
Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GABRR3 binder may also engage these)

Protein	Name	Similarity
P50573	—	0.993	P50573 →
P47742	—	0.989	P47742 →
P56476	—	0.984	P56476 →
GABRR2	Gamma-aminobutyric acid receptor subunit rho-2	0.983	landscape →
P50572	—	0.983	P50572 →
GABRR1	Gamma-aminobutyric acid receptor subunit rho-1	0.981	landscape →
Q0II76	—	0.980	Q0II76 →
P56475	—	0.975	P56475 →
Q08832	—	0.973	Q08832 →
P02713	—	0.965	P02713 →
P02714	—	0.965	P02714 →
Q9PTS8	—	0.963	Q9PTS8 →
Q94900	—	0.963	Q94900 →
Q68RJ7	—	0.963	Q68RJ7 →
P26714	—	0.963	P26714 →
CHRNA9	Neuronal acetylcholine receptor subunit alpha-9	0.960	landscape →
GLRA3	Glycine receptor subunit alpha-3	0.959	landscape →
P02717	—	0.959	P02717 →
P43144	—	0.957	P43144 →
Q91XP5	—	0.955	Q91XP5 →
P05376	—	0.953	P05376 →
P49580	—	0.953	P49580 →
P24524	—	0.953	P24524 →
Q8JFN7	—	0.952	Q8JFN7 →
P04759	—	0.952	P04759 →
P20782	—	0.951	P20782 →
P25110	—	0.949	P25110 →
GLRA2	Glycine receptor subunit alpha-2	0.949	landscape →
GLRA1	Glycine receptor subunit alpha-1	0.948	landscape →
P02716	—	0.947	P02716 →